Hansgeorg Müller
Innsbruck Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hansgeorg Müller.
European Journal of Immunology | 2005
Hansgeorg Müller; Susanne Hofer; Nicole C. Kaneider; Hannes Neuwirt; Birgit A. Mosheimer; Gert Mayer; Günther Konwalinka; Christine Heufler; Martin Tiefenthaler
The potent immunomodulator FTY720 elicits immunosuppression via acting on sphingosine 1‐phosphate receptors (S1PR), thereby leading to an entrapment of lymphocytes in the secondary lymphoid tissue. To elucidate the potential in vitro effects of this drug on human monocyte‐derived DC, we used low nanomolar therapeutic concentrations of FTY720 and phosphorylated FTY720 (FTY720‐P) and investigated their influence on DC surface marker expression, protein levels of S1PR and DC effector functions: antigen uptake, chemotaxis, cytokine production, allostimulatory and Th‐priming capacity. We report that both FTY720 and FTY720‐P reduce chemotaxis of immature and mature DC. Mature DC generated in the presence of FTY720 or FTY720‐P showed an impaired immunostimmulatory capacity and reduced IL‐12 but increased IL‐10 production. T cells cultured in the presence of FTY720‐ or FTY720‐P‐treated DC showed an altered cytokine production profile indicating a shift from Th1 toward Th2 differentiation. In treated immature and mature DC, expression levels for two S1PR proteins, S1P1 and S1P4, were reduced. We conclude that in vitro treatment with FTY720 affects DC features that are essential for serving their role as antigen‐presenting cells. This might represent a new aspect of the overall immunosuppressive action of FTY720 and makes DC potential targets of further sphingolipid‐derived drugs.
Journal of The American Academy of Dermatology | 2008
Hansgeorg Müller; Cornelia Gattringer; Bernhard Zelger; Reinhard Höpfl; Klaus Eisendle
Pityriasis rubra pilaris (PRP) is a rare, chronic papulosquamous disorder of unknown etiology that often progresses to disabling palmoplantar keratoderma and erythroderma. There is currently no universally effective treatment for PRP, and some cases are resistant to multiple topical and systemic therapies. Systemic retinoids, methotrexate, several immunosuppressive agents, fumaric acid esters, stanozolol, and phototherapy have all been used with varying degrees of success. Recently, a few reports have appeared in the literature concerning the use of biologics in combination therapies and/or in refractory PRP cases. We report a case of type I adult-onset PRP successfully treated with infliximab monotherapy as initial systemic therapy, and provide a comprehensive literature review on biologic therapy for PRP. The complete and persistent response to infliximab in our patient and in the previously reported cases confirms a role for anti-tumor necrosis factor-alfa therapy as an effective option in the treatment of PRP. Further studies are warranted to evaluate possible differences in efficacy among the different biologics.
British Journal of Dermatology | 2009
Mirjana Ziemer; Klaus Eisendle; Hansgeorg Müller; Bettina Zelger
Background Lymphocytic infiltration of the skin (LIS) and reticular erythematous mucinosis (REM) are characterized histologically by an inflammatory cutaneous lymphocytic infiltrate similar to the histological appearance of pseudolymphoma.
Archives of Dermatological Research | 2012
Laura Kühnelt-Leddihn; Hansgeorg Müller; Klaus Eisendle; Bernhard Zelger; Georg Weinlich
Multiple functional implications have been suggested for a limited number of chemokines and their cognate receptors in melanoma pathogenesis. The purpose of this study was to investigate the potential role of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 as prognostic markers in human primary cutaneous melanoma. Chemokine receptor expression was analyzed by immunohistochemistry in a total of 38 patients with cutaneous melanoma. Results were statistically correlated with melanoma features and clinical disease progression. No significant correlation between overexpression of CXCR4 or CCR9 and survival or prognosis was found. CCR7 overexpression was associated with significantly lower survival (0.005 log rank) and shorter time to progression (0.009 log rank)—similar to CCR10 overexpression (lower survival: 0.001 log rank, shorter time to progression: 0.002 log rank). In addition, CCR7 overexpression correlated with expression of metallothionein, while CCR10 seems to be associated with cerebral metastases. Two chemokine receptors permitting the identification of high-risk patients were identified: CCR7 and CCR10 overexpressions were found to be associated with a worse outcome of disease course independent of Breslow’s tumor thickness and Clark level, thus representing possible additional prognostic markers.
British Journal of Dermatology | 2011
Hansgeorg Müller; Klaus Eisendle; Wolfgang Bräuninger; Heinz Kutzner; Lorenzo Cerroni; Bettina Zelger
Background The incidence of syphilis is increasing in many parts of the world including a re‐emergence in Western Europe and North America. Depending on the disease stage, direct detection of Treponema pallidum in mucocutaneous lesions of syphilis may be difficult and histopathological findings are not always straightforward. Thus, the correct histological diagnosis may be challenging.
Journal of The American Academy of Dermatology | 2010
Barbara C. Böckle; Manuel Wilhelm; Hansgeorg Müller; Claudia Götsch; Norbert Sepp
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autosomal recessive disease caused by mutations in the AIRE gene. We report the case of a female patient with a 967-979del13 mutation in the AIRE gene. Her medical history included autoimmune hypoparathyroidism, Addison disease, and chronic mucocutaneous candidiasis. At the age of 40, she developed multiple white verrucous plaques on the oral mucosa. Histologically, the lesions appeared as moderately differentiated squamous cell carcinomas. The patient subsequently developed multiple local recurrences and therefore required repeated surgery. Notably, a higher incidence rate of oral and esophageal squamous cell carcinoma has been observed in this syndrome. However, the critical pathogenetic pathways implicated in squamous cell carcinoma development in APECED are far from being well understood.
Acta Dermato-venereologica | 2010
Cornelia Gattringer; Christine Scheurecker; Reinhard Höpfl; Hansgeorg Müller
We report here two cases of men, aged 46 and 23 years, with refractory chronic venous leg ulcers in association with sex chromosome aberrations: one with a 47,XXY/48,XXXY karyotype (Klinefelter syndrome) and the other with a 47,XYY karyotype (Jacob syndrome). In both patients, the occurrence of leg ulcers was the reason for seeking medical care; their medical history was other-wise unremarkable. Chromosomal analyses were performed due to the unusually young age for development of venous leg ulcers. The pathophysiology behind the occurrence of venous leg ulcers in patients with numerical aberrations of the sex chromosomes is incompletely understood. Involvement of elevated plasminogen activator inhibitor-1 levels in the pathogenesis of venous leg ulcers has been reported in patients with Klinefelter syndrome. Notably, our patient with 47,XXY/48,XXXY presented with androgen deficiency but normal plasminogen activator inhibitor-1 activity.
British Journal of Dermatology | 2008
Hansgeorg Müller; Klaus Eisendle; Günther Gastl; Reinhard Höpfl; Bettina Zelger
and fexofenadine medication to 10 mg once daily 4 and 6 weeks after initiation of treatment, respectively. Patient 2 discontinued montelukast medication after 8 weeks of treatment. No UV irradiation for maintenance of UV tolerance was required. All patients were recommended still to apply high protection factor sunscreens on habitually sun-exposed skin areas on a regular basis. We speculate that ongoing tolerance after reduction of medication was due to the ability to maintain ambient UV exposure during the subsequent months. Taken together, this antihistamine combination regimen has the potential to be particularly helpful for patients with severe forms of solar urticaria with systemic reactions.
Journal of Gastroenterology and Hepatology | 2011
Klaus Eisendle; Hansgeorg Müller; Elisabeth Ortner; Heribert Talasz; Ivo Graziadei; Wolfgang Vogel; Reinhard Höpfl
Background and Aim: Generalized pruritus of unknown origin (PUO) is a highly distressing condition that is unrelated to any underlying dermatologic or systemic disorder (e.g. cholestasis). Little is known about the potential contribution of elevated total serum bile acid (TSBA) levels to PUO. Our aim in the present study was to investigate the role of elevated TSBA levels in patients with PUO and the efficacy of ursodeoxycholic acid (UDCA) and cholestyramine therapy.
Modern Pathology | 2017
Klaus G. Griewank; Hansgeorg Müller; Louise A Jackett; Michael Emberger; Inga Möller; Johannes van de Nes; Lisa Zimmer; Elisabeth Livingstone; Thomas Wiesner; Simone L. Scholz; Ioana Cosgarea; Antje Sucker; Tobias Schimming; Uwe Hillen; Bastian Schilling; Annette Paschen; Henning Reis; Thomas Mentzel; Heinz Kutzner; Arno Rütten; Rajmohan Murali; Richard A. Scolyer; Dirk Schadendorf
Blue nevi are melanocytic tumors originating in the cutaneous dermis. Malignant tumors may arise in association with or resembling blue nevi, so called ‘blue nevus-like melanoma’, which can metastasize and result in patient death. Identifying which tumors will behave in a clinically aggressive manner can be challenging. Identifying genetic alterations in such tumors may assist in their diagnosis and prognostication. Blue nevi are known to be genetically related to uveal melanomas (eg, both harboring GNAQ and GNA11 mutations). In this study, we analyzed a large cohort (n=301) of various morphologic variants of blue nevi and related tumors including tumors diagnosed as atypical blue nevi (n=21), and blue nevus-like melanoma (n=12), screening for all gene mutations known to occur in uveal melanoma. Similar to published reports, we found the majority of blue nevi harbored activating mutations in GNAQ (53%) or GNA11 (15%). In addition, rare CYSLTR2 (1%) and PLCB4 (1%) mutations were identified. EIF1AX, SF3B1, and BAP1 mutations were also detected, with BAP1 and SF3B1 R625 mutations being present only in clearly malignant tumors (17% (n=2) and 25% (n=3) of blue nevus-like melanoma, respectively). In sequencing data from a larger cohort of cutaneous melanomas, this genetic profile was also identified in tumors not originally diagnosed as blue nevus-like melanoma. Our findings suggest that the genetic profile of coexistent GNAQ or GNA11 mutations with BAP1 or SF3B1 mutations can aid the histopathological diagnosis of blue nevus-like melanoma and distinguish blue nevus-like melanoma from conventional epidermal-derived melanomas. Future studies will need to further elucidate the prognostic implications and appropriate clinical management for patients with tumors harboring these mutation profiles.